PhaseBio Pharmaceuticals

Recent Finacing

Series D

Recent Raise

$34M

PhaseBio Pharmaceuticals is a clinical-stage biopharma developing long-acting peptide therapeutics for cardiopulmonary orphan diseases using a proprietary elastin-like polypeptide (ELP) platform to extend half-life and enable less-frequent dosing.

Founded 2002

Pennsylvania, United States

51-100

Publicly Traded

phasebio.com

Highlights

Focus Areas

Biotechnology

Medical

Medical Device

Pharmaceutical

Recent Investors

O

Financials

$167.3M

Total Raised

7

Funding rounds

13

Investors

Team

Upgrade to view the team

See the team members at PhaseBio Pharmaceuticals.